Technical Analysis for BFRG - Bullfrog AI Holdings, Inc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.69 | -2.31% | -0.04 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Reversal New Lows Setup | Bearish Swing Setup | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Narrow Range Bar | Range Contraction | -2.31% | |
| New 52 Week Low | Weakness | -2.31% | |
| Wide Bands | Range Expansion | -2.31% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 9 hours ago |
| Outside Day | about 9 hours ago |
| Down 3% | about 9 hours ago |
| Fell Below Previous Day's Low | about 9 hours ago |
| Down 2 % | about 9 hours ago |
Get a Trading Sidekick!
- Earnings date: Unknown
Bullfrog AI Holdings, Inc Description
BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. BullFrog AI Holdings, Inc. was founded in 2017 and is based in Gaithersburg, Maryland.
Classification
Sector: Healthcare
Industry: Health Information Services
Keywords: Medicine Artificial Intelligence Machine Learning Obesity Hepatitis Steatohepatitis Human Diseases Non Alcoholic Fatty Liver Disease Liver Disease Hepatocellular Carcinoma Histopathology Fatty Liver Disease Human Cancer Si RNA Treatment Of Human Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.35 |
| 52 Week Low | 1.65 |
| Average Volume | 76,293 |
| 200-Day Moving Average | 3.27 |
| 50-Day Moving Average | 2.68 |
| 20-Day Moving Average | 2.30 |
| 10-Day Moving Average | 1.86 |
| Average True Range | 0.18 |
| RSI (14) | 21.88 |
| ADX | 41.72 |
| +DI | 11.83 |
| -DI | 33.20 |
| Chandelier Exit (Long, 3 ATRs) | 2.41 |
| Chandelier Exit (Short, 3 ATRs) | 2.19 |
| Upper Bollinger Bands | 3.24 |
| Lower Bollinger Band | 1.35 |
| Percent B (%b) | 0.18 |
| BandWidth | 82.30 |
| MACD Line | -0.32 |
| MACD Signal Line | -0.27 |
| MACD Histogram | -0.0538 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.04 | ||||
| Resistance 3 (R3) | 2.06 | 1.97 | 1.98 | ||
| Resistance 2 (R2) | 1.97 | 1.88 | 1.96 | 1.96 | |
| Resistance 1 (R1) | 1.83 | 1.83 | 1.79 | 1.81 | 1.94 |
| Pivot Point | 1.74 | 1.74 | 1.72 | 1.73 | 1.74 |
| Support 1 (S1) | 1.60 | 1.65 | 1.56 | 1.58 | 1.44 |
| Support 2 (S2) | 1.51 | 1.60 | 1.50 | 1.42 | |
| Support 3 (S3) | 1.37 | 1.51 | 1.40 | ||
| Support 4 (S4) | 1.35 |
